These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27956185)

  • 1. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical examination of the definition of 'psychoactive effect' in Australian drug legislation.
    Barratt MJ; Seear K; Lancaster K
    Int J Drug Policy; 2017 Feb; 40():16-25. PubMed ID: 27884504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 6. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New psychoactive substances legislation in Ireland - Perspectives from academia.
    Kavanagh PV; Power JD
    Drug Test Anal; 2014; 6(7-8):884-91. PubMed ID: 24478277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory approaches to new psychoactive substances (NPS) in the European Union.
    Hughes B; Griffiths P
    Addiction; 2014 Oct; 109(10):1591-3. PubMed ID: 25163707
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract]   [Full Text] [Related]  

  • 12. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
    Rizwan SB; Vernall AJ
    BMJ; 2017 Mar; 356():j1195. PubMed ID: 28314708
    [No Abstract]   [Full Text] [Related]  

  • 13. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of policy: understanding the process of policy development.
    Ryder D
    Addiction; 1996 Sep; 91(9):1265-70. PubMed ID: 8854357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New psychoactive substances: a public health issue.
    Guirguis A
    Int J Pharm Pract; 2017 Oct; 25(5):323-325. PubMed ID: 28895252
    [No Abstract]   [Full Text] [Related]  

  • 17. Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations.
    Heyerdahl F; Hovda KE; Giraudon I; Yates C; Dines AM; Sedefov R; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2014 Dec; 52(10):1005-12. PubMed ID: 25361166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New psychoactive substances in Taiwan: challenges and strategies.
    Feng LY; Li JH
    Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding and managing the new psychoactive substances phenomenon: a holistic approach.
    Zamengo L; Frison G; Zwitser G
    J Public Health Policy; 2019 Jun; 40(2):217-235. PubMed ID: 30504846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.